Meeting Unmet Needs of Neurodegeneration and Disorders of Cognition by Targeting the NMDA Receptor with Dr. Aaron Koenig and Mike Quirk Sage Therapeutics

Dr. Aaron Koenig, Senior Medical Director and Mike Quirk, Vice President of pharmacology Sage Therapeutics focus on disorders of cognition and diseases that reflect determinants of impaired cognition such as Alzheimer’s, Parkinson’s and Huntington’s. Their drug Sage-718, a novel mechanism of action, targets a protein in the brain, the NMDA receptor, thought to be the brain’s coincidence detector designed to link together information that flows from different neural pathways and perhaps correct some of the symptoms causing functional impairment.

@SageBiotech #Alzheimers #Parkinsons #Huntingtons #executivefunction #cognition #neurodegeneration

Download the transcript here


Share on facebook
Share on twitter
Share on linkedin
Related Post


Sign up for Breaking News, Newsletter, Blog Posts and Special Deals from 1631 Digital and their media/marketing partners.

Subscribers agree to be contacted from 1631 Digital News and/or their media/marketing partners for breaking news alerts, newsletters and special media marketing offers via email, mail and/or texting communication.